Prevalence of Oral Lesions in COVID-19 Patients

NCT04917549 | Completed

• 1 other identifier: KD/04/20
• Study Type: observational
• Target: 124
• Locations: 1 country
• Sites: 1

Brief Summary

Recently, a new coronavirus disease 2019 (COVID-19) has appeared and caused an unprecedented pandemic which is considered as an urgent threat to health authorities worldwide. Several symptoms are observed which are fever, cough, shortness of breath, headache, runny nose, muscle pain, fatigue, arthralgia, sputum production, conjunctivitis, diarrhea. Susceptibility, genetics, systematic diseases, population, gender, and age are crucial considerations for the onset and progression of the viral infection. The patients suffering from asthma or pulmonary deficiency are at high risk of mortality. A metallopeptidase, angiotensin-converting enzyme 2 (ACE2) is considered as the functional receptor for SARS-CoV-2 and it was isolated from a COVID-19 patient. ACE2 was recognized in type I and type II alveolar epithelial cells in both nasal and oral mucosa, in the nasopharynx, in the smooth muscle cells and endothelium of vessels in the stomach and the skin, distinctly in the basal cell layer of the epidermis extending to the basal cell layer of hair follicles, and in the basal layer of the non-keratinizing squamous epithelium. In order to study the possible routes of SARS-CoV-2 infection on the oral mucosa, we investigated whether oral lesions mainly affect the tongue mucosa due to higher ACE2-expressing cell composition and proportion more than that in other oral tissues. Moreover, appearance of oral lesions were as a result of SARS-CoV-2 infection or as a side effect of certain drugs for COVID-19 treatment was evaluated.

Conditions

Oral Lesions; COVID-19; Angiotensin-converting Enzyme 2

Outcome Measures

Primary Outcomes (1)

• site of mucosa affected by oral lesions

  Number and site of oral lesions that affect the oral cavity

  1 month

Secondary Outcomes (1)

• treatment of the patients

  1 month

Study Arms (1)

Patients diagnosed with COVID-19

Other: detection of oral lesions

Interventions

detection of oral lesions OTHER

oral lesions in patient diagnosed with COVID-19

Patients diagnosed with COVID-19

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All data was taken for each patient on the admission and during the hospital stay.

You may qualify if:

• age \> 18 years.
• laboratory-confirmed COVID-19 infection (reverse transcription-polymerase chain reaction, RT-PCR).

You may not qualify if:

• patients without a laboratory-confirmed diagnosis of COVID-19 infection.
• patients with olfactory or gustatory dysfunctions before the epidemic.
• patients with some malignant neoplasms.
• patients with neurodegenerative disorders.

Sponsors & Collaborators

• Kafrelsheikh University: lead

Study Sites (1)

Dalia Rasheed Issa

Kafr ash Shaykh, Kafr el-Sheikh Governorate, 33511, Egypt

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Dalia R Issa, PhD

  Kafrelsheikh University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Month
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: principal invistigator

Study Record Dates

• First Submitted: June 3, 2021
• First Posted: June 8, 2021
• Study Start: September 2, 2020
• Primary Completion: June 10, 2021
• Study Completion: June 10, 2021
• Last Updated: April 4, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)